{"id":685015,"date":"2022-09-14T06:33:45","date_gmt":"2022-09-14T10:33:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/"},"modified":"2022-09-14T06:33:45","modified_gmt":"2022-09-14T10:33:45","slug":"ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/","title":{"rendered":"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:center\">\n          <em>Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron<\/em>\n        <\/li>\n<\/ul>\n<ul>\n<li style=\"text-align:center\">\n          <em>Ocugen has North American commercialization rights for BBV152, commercialized as COVAXIN\u2122<\/em>\n        <\/li>\n<\/ul>\n<p>MALVERN, Pa., Sept.  14, 2022  (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the publication <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qpv6B2KLIX49DTYhhNSXNEIVuHylxkcHgABZxyFfmGkuwMVKRm2fP_URg7QXoXo3d17JmHwkNdERIJ1S_6payyjL5qR4WkHLV1gt6dH-Eq2vVDmZrRJaaM18Ctv1P2jEQO-eJ6WAJJDQWBg9dhhMKM62bbdWQQTJ1QYbhYI91BKDyL1I_v-Z4BxKHNoxG9CWqk9KForsoEYXfJCc3sAVo8RMqOVtApvlurSdPK-zGTyr4FhnhW8UEk5kVeVRxXSeTsk3C2lKTgm-wyirJBs-s6WxQC62JuUEg5BU9Mp1yZfs2DciYfEAKf4FWA_d4zub45_agzRj9JhksgKoJWmasfUaBS-1ksVJekJolndXRM-epYe3x43EpjXeMrcXCirXNloPYCxxnw0X7PJpeZxg0HnFxfRglzj0y0zNeQcvVYa4GuTlIZ5uv0yvKtBGIdq-BD3knrFxb51qn2u6_gGRWQR4e_smM1sPIxrK_0p0B98=\" rel=\"nofollow noopener\" target=\"_blank\">\u201cA comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects\u201d<\/a> appeared in <em>Frontiers in Immunology.<\/em> BBV152, commercialized as COVAXIN\u2122, is developed and manufactured by Ocugen\u2019s partner\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RWnCoRjL9kRRrKl3Oj02JS4IER_d23MU_QQhaDanbkBqI-M4k6C51jbUfEUJ-xTlBwZV_WxvDvUSxtNkxe59eJfZKrtCrHgQL2Ty_3ztrwE=\" rel=\"nofollow noopener\" target=\"_blank\">Bharat Biotech<\/a>, a global leader in vaccine innovation based in Hyderabad, India. BBV152 is currently authorized by the World Health Organization, authorized under Emergency Use Authorization in 28 countries, and accepted as a COVID-19 vaccine to travel into over 85 countries. It is under clinical investigation by Ocugen in the United States for use in adults aged 18 years and older.<\/p>\n<p>This review by Dotiwala and Upadhyay provides a detailed analysis of the immunogenicity, safety, and efficacy of BBV152\u2014a whole virus inactivated vaccine and an important tool in the fight to control the COVID-19 pandemic. Additionally, BBV152 has a broader impact on public health, as it induces high neutralization efficacy against different SARS-CoV-2 variants of concern.<\/p>\n<p>\u201cUnfortunately, the COVID-19 pandemic is not yet over, despite the introduction of effective vaccines and a greater understanding of COVID-19 pathogenesis and transmission dynamics,\u201d said David Fajgenbaum, MD, MBA, MSc, Assistant Professor of Medicine, Translational Medicine &amp; Human Genetics, University of Pennsylvania, and Ocugen Vaccine Scientific Advisory Board member. \u201cThis study demonstrates durability through immune memory and a broader immune response with BBV152 and provides further evidence that additional vaccine options\u2014including those built on a traditional vaccine platform\u2014are needed.\u201d<\/p>\n<p>Findings include:<\/p>\n<ul type=\"disc\">\n<li>77.8% and 93.4% protection from symptomatic COVID-19 disease and severe symptomatic COVID-19 disease respectively.<\/li>\n<li>Studies in pediatric populations show superior immunogenicity (geometric mean titer ratio of 1.76 compared to an adult) with a seroconversion rate of &gt;95%.<\/li>\n<li>Reactogenicity and safety profiles were comparable across all pediatric age groups between 2-18 yrs.<\/li>\n<\/ul>\n<p>The study concludes that BBV152 is a suitable alternative to mRNA vaccines.<\/p>\n<p>\n        <strong>About Ocugen, Inc<\/strong>.<br \/>Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient\u2019s lives through courageous innovation\u2014forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.\u00a0<br \/>Discover more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7RmS3BT0E2GqZZqngf7d-7ASxp7VUgZXntv-9H-UAlgg3N3z2gazpaSAleC41knl09ykfqlfAQYXyJetZ5y6tw==\" rel=\"nofollow noopener\" target=\"_blank\">www.ocugen.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NnUfaTusYoWwypE1I8RBFfhaOD-dqwQI2W9ySmHVqK21-HjnicasraXlA7gkXrAnmGkYVsFimaj0QoWHC_fFLw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iTw_JdiFBDypESuW6Wu04HFLBA-HhybO9MY4pjiPyUPSmjWdJmV_tWUybnZNbDViaoTfKYNo6MRCpiXzsn6WyWdp0bZJMBdMuQuKYDYwEHg=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled \u201cRisk Factors\u201d in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.<\/em>\n      <\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Tiffany Hamilton<\/strong><br \/>\n        <br \/>\n        <strong>Head of Communications<\/strong><br \/>\n        <br \/>\n        <strong>IR@ocugen.com<\/strong>\n      <\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MDZmNjEzYmItMDcyNC00MDE4LTk1NjAtM2Y1ZTA3N2NhMTZiLTExOTYwNzM=\/tiny\/Ocugen.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron Ocugen has North American commercialization rights for BBV152, commercialized as COVAXIN\u2122 MALVERN, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the publication \u201cA comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects\u201d appeared in Frontiers in Immunology. BBV152, commercialized as COVAXIN\u2122, is developed and manufactured by Ocugen\u2019s partner\u00a0Bharat Biotech, a global leader in vaccine innovation based in Hyderabad, India. BBV152 is currently authorized by the World Health Organization, authorized under Emergency Use Authorization in 28 countries, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-685015","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron Ocugen has North American commercialization rights for BBV152, commercialized as COVAXIN\u2122 MALVERN, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the publication \u201cA comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects\u201d appeared in Frontiers in Immunology. BBV152, commercialized as COVAXIN\u2122, is developed and manufactured by Ocugen\u2019s partner\u00a0Bharat Biotech, a global leader in vaccine innovation based in Hyderabad, India. BBV152 is currently authorized by the World Health Organization, authorized under Emergency Use Authorization in 28 countries, &hellip; Continue reading &quot;Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T10:33:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology\",\"datePublished\":\"2022-09-14T10:33:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/\"},\"wordCount\":672,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/\",\"name\":\"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=\",\"datePublished\":\"2022-09-14T10:33:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/","og_locale":"en_US","og_type":"article","og_title":"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology - Market Newsdesk","og_description":"Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron Ocugen has North American commercialization rights for BBV152, commercialized as COVAXIN\u2122 MALVERN, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the publication \u201cA comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects\u201d appeared in Frontiers in Immunology. BBV152, commercialized as COVAXIN\u2122, is developed and manufactured by Ocugen\u2019s partner\u00a0Bharat Biotech, a global leader in vaccine innovation based in Hyderabad, India. BBV152 is currently authorized by the World Health Organization, authorized under Emergency Use Authorization in 28 countries, &hellip; Continue reading \"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-14T10:33:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology","datePublished":"2022-09-14T10:33:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/"},"wordCount":672,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/","name":"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=","datePublished":"2022-09-14T10:33:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjM5MCM1MTUxNjkxIzIxODQ1MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-announces-publication-of-a-comprehensive-review-of-bbv152-in-frontiers-in-immunology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/685015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=685015"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/685015\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=685015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=685015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=685015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}